Unlocking the power of real-world data – New podcast episode

Research / 31 March 2023

Real-world data is a rich source of evidence for pharmacovigilance, but there are challenges yet to be faced before unlocking its true potential as a resource.


Real-world data, or observational data collected during routine clinical care, could be a valuable source of evidence in pharmacovigilance. However, there are still hurdles to overcome before it can deliver on that value.

In the latest episode of the Drug Safety Matters podcast, Federica Santoro and Patrick Ryan from Johnson & Johnson discuss the challenges of using real-world data for patient safety and how this resource may be harnessed for pharmacovigilance through some ‘proof of concept’ projects such as OHDSI and EHDEN.

Like what you hear? Then subscribe to the podcast by visiting the Drug Safety Matters website.

You may also like


Looking beyond age to understand adverse reaction risk in older patients

When it comes to pharmacovigilance in older patients, age alone is insufficient as a measure of adverse reaction risk. Here is what we should consider instead.

Research / 13 May 2024

When medicines change our behaviour – New podcast out now

Adverse effects to medicines are not just physical in nature, but can manifest as behavioural side-effects too. How do we diagnose and treat these complex ADRs?

Research / 02 May 2024

Updating our approach to study adverse reactions

The traditional “drug-event combination” approach is too simplistic for complex side effects such as behavioural changes. We must adjust our methodology to address this intricacy.

Research / 29 May 2024

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies.

Find out more